This corrects the article DOI: 10.1038/leu.2016.388.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/leu.2017.219 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.
Biomedicines
July 2023
Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
Article Synopsis
- Multiple myeloma (MM) is a type of cancer that affects plasma cells in the bone marrow and leads to various health issues like bone pain, kidney damage, and infections.
- Historically considered incurable with a life expectancy of about three years post-diagnosis, recent advancements in treatment have notably improved patient outcomes and survival rates.
- New therapies include drugs like thalidomide, lenalidomide, and proteasome inhibitors, alongside monoclonal antibodies and CAR-T therapies, which target cancerous plasma cells more effectively.
Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
J Clin Oncol
September 2023
Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE.
Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory multiple myeloma (MM) have been poor because of a dearth of effective treatment options. However, the advent of chimeric antigen receptor (CAR) T-cell and T-cell redirecting bispecific antibody (BsAb) therapies has led to unprecedented response rates and durations of response in heavily relapsed/refractory (R/R) populations. Currently, two B-cell maturation antigen (BCMA)-directed CAR T-cell therapies (idecabtagene vicleucel and ciltacabtagene autoleucel) as well as one BCMA/CD3 BsAb (teclistamab) have been approved for late-line (greater than four previous lines) R/R MM in the United States.
View Article and Find Full Text PDFBispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth.
Cancers (Basel)
May 2022
Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA.
BCMA antigen is overexpressed in multiple myeloma cells and has been shown to be a promising target for novel cellular and antibody therapeutics. The humanized BCMA (clone 4C8A) antibody that effectively targeted multiple myeloma in a CAR (chimeric antigen receptor) format was used for designing several formats of bispecific BCMA-CD3 antibodies. Several different designs of univalent and bivalent humanized BCMA-CD3 CrossMAB and BCMA-FAB-CD3 ScFv-Fc antibodies were tested for binding with BCMA-positive cells and T cells and for killing by real time cytotoxic activity and IFN-gamma secretion with CHO-BCMA target cells and with multiple myeloma MM1S and H929 cell lines.
View Article and Find Full Text PDFB-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ɛ (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA-positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!